Cancer Biology in Ulcerative Colitis and Potential Use in Endoscopic Surveillance

Shapiro, Bradley D.; Lashner, Bret A.

doi:10.1016/s1052-5157(18)30299-x

Cited by 24 publications

(6 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The surveillance for CRC in patients with inflammatory bowel disease is usually performed by colonoscopy with biopsies of suspicious lesions. 24,27…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum p53 Antibodies in Patients Affected with Ulcerative Colitis

Cioffi¹,

Riegler²,

Vietri³

et al. 2004

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

During tumor progression, the accumulation in genetic alterations is a fundamental characteristic of malignant cells. p53 gene is frequently mutated in human tumor. Cellular accumulation of p53 protein can initiate an immune response with generation of circulating anti-p53 antibodies. Patients with ulcerative colitis have an increased risk of developing colorectal neoplasm and, among the different genes involved in carcinogenesis, p53 may play a key role. Sera and tissues from 97 patients (M = 53, F = 44) affected with ulcerative colitis (UC) were collected. Serum anti-p53 antibodies (p53Abs) were detected in duplicate with ELISA method. Serum p53Abs were detectable in 9.3% (9/97) of patients affected with UC. In these patients, the titer of p53Ab ranged between 3.1 and 14.9 U/mL (mean, 6.6 U/mL; SD, 4.64). Serum p53Abs were undetectable in control group. With an immunoluminometric assay for the quantitative determination of p53, we found 9/97 positive samples (> or = 0.69 mg/mg of total proteins). In contrast, the samples of the remaining 89 patients were found negative (< or = 0.30 mg/mg of total proteins). All patients that were positive for anti-p53 antibodies were also positive with p53 protein accumulation in the tissue of colonic biopsies. In UC, follow-up with colonoscopy has several advantages. The colonoscopy is not well accepted by patients, and poor patient observance has the potential to seriously devalue the technique as a screening tool, despite practical considerations of competence within endoscopy service. Serological detection of p53Abs by enzyme-linked immunosorbent assay (ELISA) is easy to perform, does not require tumor specimen, can be performed in a routine diagnostic procedure, may be used in clinical practice, and could facilitate physicians in patient monitoring. We suggest that serum p53Abs assessment, indirect marker for p53 gene mutations, and abnormally high p53 protein levels could be considered to have a potential for use as a complementary test to improve surveillance program performance.

show abstract

“…The surveillance for CRC in patients with inflammatory bowel disease is usually performed by colonoscopy with biopsies of suspicious lesions. 24,27…”

Section: Discussionmentioning

confidence: 99%

“…In addition, short duration of the disease, no dysplasia, and no family history of CRC are considered low‐risk factors. 19–21,23,24 In the literature is reported the detection of serum p53Abs in 3/61 (4.9%) UC patients. 25…”

mentioning

confidence: 99%

Serum p53 Antibodies in Patients Affected with Ulcerative Colitis

Cioffi¹,

Riegler²,

Vietri³

et al. 2004

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…81 Consideration should be made for all biopsies con-cerning for high-grade dysplasia to be confirmed by 2 independent Gi pathologists when possible. 79,80 unlike sporadic cases, cancer in uC patients may not always follow a progression from normal epithelium to low-grade dysplasia, high-grade dysplasia, and finally invasive malignancy.…”

Section: Total Proctocolectomy With or Without Ipaa Is Recommended mentioning

confidence: 99%

Practice Parameters for the Surgical Treatment of Ulcerative Colitis

Ross

Steele

Varma

et al. 2014

Diseases of the Colon &Amp; Rectum

159

View full text Add to dashboard Cite

“…p53 gene mutations with detection of the mutated protein products using immunohistochemistry offer promising possibilities as a test complementary to dysplasia for use in cancer surveillance programs. 24 Meanwhile, it has been shown that patients with various types of neoplasia have p53 antibodies (Abs) in their sera. 25,26 Recently, an approach for diagnosis of p53 alterations has been developed, which consists of detection of p53 Abs in sera from patients affected by a wide variety of cancers by enzyme-linked immunosorbent assay (ELISA).…”

mentioning

confidence: 99%